Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Schizophrenia
Interventions
Paliperidone IR (Period 1), Paliperidone palmitate F015 (Panel A: treatment group 1), Paliperidone palmitate F015 (Panel A: treatment group 2), Paliperidone palmitate F015 (Panel B: treatment group 1), Paliperidone palmitate F015 (Panel B: treatment group 2), Paliperidone palmitate F015 (Panel B: treatment group 3), Paliperidone palmitate F015 (Panel B: treatment group 4), Paliperidone palmitate F015 (Panel B: treatment group 5), Paliperidone palmitate F016, Paliperidone palmitate F015 (Panel D: treatment group 1), Paliperidone palmitate F015 (Panel D: treatment group 2), Paliperidone palmitate F015 (Panel D: treatment group 3), Paliperidone palmitate F015 (Panel D: treatment group 4)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
10
States / cities
Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 7 more
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
HIV Infections
Interventions
Nevirapine Immediate Release (IR), Nevirapine Extended Release (XR)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
3 Years to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Conditions
Healthy
Interventions
Pregabalin ER
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Pain
Interventions
Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah
Conditions
Allergic Rhinitis Due to Grass Pollens
Interventions
300 IR, Placebo
Drug
Lead sponsor
Stallergenes Greer
Industry
Eligibility
18 Years to 65 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Normal, Illinois • Lexington, Kentucky • Owensboro, Kentucky + 16 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin immediate release
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
45
States / cities
Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications

NCT04885530
Conditions
Covid19
Interventions
Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
10,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Conditions
HIV Infections
Interventions
INCB009471, Placebo comparator
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more
Conditions
Rhinitis, Allergic, Perennial, House Dust Mite Allergy
Interventions
300 IR, Placebo
Biological
Lead sponsor
Stallergenes Greer
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Seizures
Interventions
Ezogabine/Retigabine IR, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
9
States / cities
Fresno, California • Santa Monica, California • Colorado Springs, Colorado + 6 more
Conditions
Rheumatoid Arthritis
Interventions
Andecaliximab, Placebo, Methotrexate, TNF Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide, Matching Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
71
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Conditions
Healthy
Interventions
Pregabalin controlled release, 330 mg, low-fat, Pregabalin controlled release, 330 mg, medium-fat, Pregabalin controlled release, 330 mg, high-fat, Pregabalin immediate release, 300 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Pharmacokinetics, Healthy Volunteer
Interventions
PF614 capsule, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Conditions
Restless Leg Syndrome
Interventions
Gabapentin immediate release, Gabapentin enacarbil extended release
Drug
Lead sponsor
Theresa Zesiewicz, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Pain
Interventions
Ibuprofen 300 mg Oral Tablet, Ibuprofen 200 mg Oral Tablet, Placebo of PR tablet, Placebo of IR tablet
Drug
Lead sponsor
Reckitt Benckiser Healthcare (UK) Limited
Industry
Eligibility
18 Years to 50 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Healthy
Interventions
Lacosamide (LCM), Carbamazepine Immediate Release (CBZ-IR)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Conditions
Ulcerative Colitis
Interventions
Mirikizumab SC, Mirikizumab IV, Placebo SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
57
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 51 more
Conditions
Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
Interventions
Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)
Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Healthy
Interventions
Canagliflozin tablets, Metformin IR tablets, Canagliflozin/metformin IR FDC tablets
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Bipolar Disorder
Interventions
Bupropion, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBI-223 oral suspension, TBI-223 enteric capsule, TBI-223 SR Tablet Prototype 1, TBI-223 SR Tablet Prototype 2, TBI-223 SR Tablet Prototype 3, TBI-223 IR Tablet, Placebo suspension
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Recruiting Phase 1 Interventional Accepts healthy volunteers

Human Models of Selective Insulin Resistance: Alpelisib, Part I

NCT06354088
Conditions
Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
Interventions
Alpelisib 300 mg, Placebo, [1-13C] sodium acetate, [6,6-2H2] D-glucose, Mixed Meal Tolerance Test, Nestlé BOOST Plus
Drug · Diagnostic Test · Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York